All In Biotech

Drug Trial Radar · NCT00189488

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation

Last checked: Nov 20, 2026Latest source record: Sep 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Dec 2005

Primary completion

Nov 2008

Study completion Aug 2013

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Amgen
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.

Conditions

  • Graft Versus Host Disease
  • Hematologic Malignancies

Interventions

  • PaliferminDrug

    Administered as an intravenous (IV) bolus.

  • PlaceboDrug

    Administered as an intravenous (IV) bolus.

  • Conditioning RegimenOther

    Each participant received 1 of the following conditioning regimens: * Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16) * TBI/VP-16 * Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible) * Busulfan (Bu)/Cy * Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\]) * Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])

  • Allogeneic stem cell transplantProcedure

    Allogeneic marrow/peripheral blood progenitor cell transplantation

  • MethotrexateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)Time frame: From transplant (Day 0) until Day 100

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.